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Adenoviruses are a group of DNA viruses currently consisting of more than 50 different recognized serotypes that have been classified into six subgroups (A-F). Adenoviruses cause a number of clinical syndromes in immune-competent individuals that are usually mild and self-limiting such as conjunctivitis, hemorrhagic cystitis, gastroenteritis, and upper respiratory tract infections. However, more severe manifestations have also been reported including hepatitis, nephritis, meningoencephalitis, and pneumonia. Adenovirus infections have become increasingly important after allogeneic hematopoietic stem cell transplantation (HSCT). They can cause significant morbidity and mortality especially in children. Risk factors include mis-matched or unrelated donor transplantation, acute graft-versus-host disease (GVHD), and isolation from multiple sites. [1] [2] [3] [4] No preventive or treatment strategy has been proven effective. Ribavirin has been used and some case reports have indicated efficacy. However, no controlled study has been performed. Cidofovir is a nucleotide analog with broad antiviral activity against primarily DNA viruses such as herpesviruses including thymidine-deficient mutants. 5 It has also been shown to have in vitro activity against adenovirus. 6 The aim of this retrospective study was to analyze the efficacy and toxicity of cidofovir given for therapy of adenovirus infection and disease after allogeneic HSCT.
Patients and methods

Questionnaire
A questionnaire was sent to 430 centers belonging to the European Group for Blood and Marrow Transplantation (EBMT). A total of 10 centers reported patients with adenovirus treated with cidofovir, who were willing to participate in the study. The questionnaire included questions regarding patient characteristics, the stem cell transplant procedure, concomitant therapies, GVHD, the diagnosis of adenovirus infection and disease, dose and duration of cidofovir therapy, side effects, and outcome. Results from a similar study analyzing the effect of cidofovir therapy for CMV infection and disease have been published. 7 
Patients
Reports on 45 patients from 10 centers were included in the study. At eight of the 10 centers, all patients with adenovirus detected were treated, while at two centers only symptomatic patients were treated with cidofovir. Patient characteristics are shown in Table 1 . The median age was 12.8 years (range 0.2-44.8), and 30 of 45 patients were younger than 16 years.
Cidofovir therapy
There was no uniform way for the dosing of cidofovir. However, 39 of 45 patients received a dosage of 5 mg/kg bodyweight/week given intravenously as induction therapy for the first two-three doses. The other six received lower doses (1 mg/kg in one patient, 3 mg/kg in two patients, and 4 mg/kg in two patients). After 2-3 doses, most patients were changed to alternative week dosing for the remainder of the therapy. Cidofovir was given for a median of 27 days (range 1-247 days). This corresponded to a median of five doses . Probenecid and extra hydration were given to all patients according to the manufacturer's specifications.
Concomitant therapy
Of the 45 patients, 25 received concomitant cyclosporin and two received tacrolimus. In addition, 25 patients received other potentially nephrotoxic agents, while 24 patients received prophylactic intravenous immunoglobulin.
Diagnosis of adenovirus infection and disease
Owing to the retrospective design of this study, there was no attempt to standardize the diagnostic methods for adenovirus infection and disease. Different techniques were used during the study for detection of adenovirus from different types of specimens such as blood, bone marrow, urine, stool, brancho-alveolar lavage (BAL) fluid, and throat specimens. These techniques included culture, antigen detection, and PCR. Biopsy specimens were analyzed by histopathology and adenovirus shown by immunocytochemistry.
Definitions
There is no accepted definition for adenovirus infection or disease. The following definitions were used in the study and were adopted from Flomenberg et al 3 Acute GVHD Grades 0-I 7 7 13 Grades II-IV 9 6 3 Chronic GVHD 2 2 0
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Failure: Death from adenovirus during or within 7 days of discontinuation of therapy or change of antiviral therapy, while adenovirus could still be detected.
Death from adenovirus: Death of a patient from which adenovirus could be identified at autopsy or death because of organ failure when adenovirus had been documented from that organ regardless of whether another pathogen was also documented.
Nonevaluable: Death from another cause within 3 days of starting cidofovir therapy.
Statistics
Comparisons between groups of patients were performed with ANOVA.
Results
Indications for therapy
In total, 45 patients were included in the study: 16 had definite adenovirus disease, 13 probable disease, and 16 asymptomatic adenovirus infections. Five patients also had CMV identified at the time of cidofovir initiation 7 and one patient had an HSV-strain resistant to acyclovir. Five patients had failed previous therapy with intravenous ribavirin given for 5-25 days. Patients who were treated for asymptomatic infection were younger than patients treated for definite (P ¼ 0.01) or probable (P ¼ 0.02) adenovirus disease.
The locations of definite adenovirus disease are shown in Table 2 . Adenovirus was identified from biopsy material in 10 patients, from BAL in six patients, and from CSF in one patient. 12 of these 16 patients, 12 had also adenovirus detected in blood.
A total of 13 patients had probable adenovirus disease; gastrointestinal tract disease in nine, urinary tract infection with hemorrhagic cystitis in three, and gastrointestinal + urinary tract infection in one patient. Seven of these patients had also adenovirus detected from blood and three patients from multiple (42) sites.
In total, 16 patients were treated for asymptomatic infections. Adenovirus was detected in blood from 12 patients, from stool in 10, from urine in four, and from throat in one patient. Nine patients had adenovirus detected from more than one site.
In total, 24 of the adenovirus strains were subtyped, 15 were of serogroup C, five of serogroup A, and three of serogroup B. One patient had two strains; one of serogroup C and the other of serogroup B.
The median times from HSCT to initiation of cidofovir therapy were 61 days (15-540) in patients with adenovirus disease, 64 days (2-266) in patients with probable disease, and 35 days in patients with an asymptomatic infection. There was a trend for asymptomatic infections to be treated earlier after transplantation than definite disease (P ¼ 0.08). The times between detection of adenovirus to initiation of therapy varied greatly. Median times were 8 days (À4 to 36) for patients with adenovirus disease , 1 day (0-42) in patients with probable disease, and 3 days (À4 to 39) in patients with an asymptomatic infection.
Outcome of cidofovir therapy
Overall results: Of the 45 patients, 31 (69%) were successfully treated with cidofovir, 10 failed, and four were not evaluable owing to early death from other causes.
Adenovirus disease: Cidofovir therapy was successful in clearing adenovirus from 10 of 16 (63%) patients with adenovirus disease. Seven patients died. Three patients were assessed by the investigators to have died of adenovirus disease, while two patients died of other causes with adenovirus still detectable. One patient died of GVHD two days after the first cidofovir dose and was assessed as not evaluable. One patient died of multiorgan failure but was adenovirus negative at autopsy (Table 3) .
Probable adenovirus disease: In total, 10 of 13 (77%) patients with symptomatic adenovirus infection were successfully treated with cidofovir, while two patients failed therapy, developed disseminated adenovirus disease and died. One patient died from GVHD.
Asymptomatic adenovirus infection: Two of 16 patients developed disseminated adenovirus disease and died, while 10 survived. Four patients died of other causes (two from leukemia relapse, one from VOD, and one patient from aspergillosis, respectively). One patient relapsed with adenovirus after discontinuation of cidofovir. The patient was not retreated and died of disseminated adenovirus disease. Nine of 12 (75%) patients, who had adenovirus viremia or DNA-emia, were successfully treated with cidofovir.
Mortality in adenovirus disease
Eight patients of 45 (18%) died of adenovirus disease; seven patients (15%) within the first 28 days after initiation of cidofovir and one later.
Overall mortality
The overall mortality was 24% at 28 days and 54% at 6 months after initiation of cidofovir therapy, indicating that this was a very high-risk patient population.
Toxicity
In total, 28 patients had no toxicity associated with cidofovir therapy, 14 (31%) developed some signs of renal toxicity, two developed bone marrow suppression, one had damaged liver function tests, and one developed nausea (possibly associated with probenicid). There was no difference in the risks for renal toxicity in patients Table 2 Types of adenovirus disease Two patients developed renal failure. Both had renal impairment before initiation of cidofovir and both died of adenovirus disease. Five patients doubled their serum creatinine, two patients had a 50% increase of the serum creatinine, and five patients developed proteinuria. Four of the 12 patients with mild to moderate grade renal toxicity died and are unassessable for long-term renal toxicity. Four of eight surviving patients normalized their renal function after discontinuation of cidofovir and four patients had some renal impairment at last follow-up (two had a 50% increase in s-creatinine above the upper normal level and two had proteinuria).
Discussion
Adenovirus infections have been associated with morbidity and mortality after HSCT. The frequencies of adenovirus infections vary greatly between different studies. Shields et al reported a 5% frequency in a study performed more than 15 years ago. Flomenberg et al reported a frequency of 21% with a much higher frequency in children (31%) than in adults (13.6%). 3 Similarly, Wasserman et al 9 reported a frequency of 18% in a pediatric population. 9 Recently, La Rosa et al 8 reported a frequency of 3% among 2889 adult bone marrow transplant patients transplanted at the MD Anderson Cancer center. 8 Reported risk factors for disease have been children compared to adults, 2 allogeneic HSCT, 2,8 total body irradiation, 1 isolation from more than one site 2, 3 ), acute GVHD, 3 and unrelated donor transplantation. 4 The risk for invasive disease has varied between 1 and 7% in published studies. 3, 4, 8, 10 Mortality has also varied between the different studies. Shields et al reported a mortality of 8% in patients with documented adenovirus infections, Baldwin et al of 6%, and La Rosa et al reported an overall mortality of 26%. There are several problems associated with comparing more recent results with results from older studies. The most important is that more patients today undergo high-risk HSCT with unrelated or haplo-mismatched family donors. This was clearly seen in our study where most patients had unrelated or mismatched donors. Another problem regarding the reported risks for disease and outcome is that there is no established definition for invasive disease, and different authors have used different definitions. We used definitions of invasive disease that correspond to the study by Flomenberg et al and La Rosa et al in the presently reported study. Today's availability of rapid and sensitive diagnostic tests might allow earlier diagnosis as patients, at a stage when antiviral therapy is more likely to succeed. Furthermore, development of new diagnostic tests will also influence definitions.
There is no proven therapy for an adenovirus infection or disease. Ribavirin has been used in case reports with varying outcome. 4, [11] [12] [13] [14] [15] [16] [17] La Rosa et al 8 showed no appreciable impact of ribavirin therapy on outcome in a recently published study including 12 patients of whom only two survived. Bordigoni et al 18 treated 13 patients with definite (three), probable (five) disease, or asymptomatic infection with ribavirin. 18 Only three of these 13 patients survived. In our study, four patients had failed ribavirin before receiving cidofovir.
Cidofovir is a broad-spectrum nucleotide antiviral that has been shown in vitro to have efficacy against adenovirus. 6 Cidofovir is nephrotoxic and there has therefore been reluctance to use it in transplant patients receiving other nephrotoxic drugs such as cyclosporin. However, we 7 recently published the EBMT experience in treating CMV infection or disease with cidofovir and showed that the risk for nephrotoxicity was 25%, and it was mild and easily manageable in the majority of the patients. At the time we initiated this retrospective study, one single case report of cidofovir therapy for adenovirus disease after HSCT had been published. 19 The results from our study show that 68% of the patients were successfully treated with cidofovir and the mortality in adenovirus disease was 14%. These results should be looked at separately for adenovirus disease and adenovirus infection without proof of organ invasion. The success rate was 63% in patients with definite adenovirus disease compared to 77% in patients with probable disease and 81% when cidofovir was given as pre-emptive therapy for an asymptomatic adenovirus infection. It is difficult to compare the results from this type of uncontrolled study with other studies and draw any conclusions about the effectiveness of a given therapy. La Rosa et al reported survival of 27% in patients with pneumonia, 39% in patients with disseminated disease (defined as adenovirus in more than one organ system), and 69% in patients with enteritis. In our study, three of six patients with pneumonia, one of two with disseminated disease but without pneumonia, and 78% of the patients with gastrointestinal disease (defined as in the study by La Rosa et al including definite and probable disease) survived. Our data also compare well with the results from a recently published small phase I/II study by Legrand et al. 20 Seven children with adenovirus gastrointestinal diseases, including one patient who also had hemorrhagic cystitis, were treated with cidofovir. Five patients recovered from the adenovirus infection, one died of progressive adenovirus disease, and one died of aspergillosis. The mortality in adenovirus pneumonia has been high in most studies and 50% survival in our study is encouraging.
A different question is if cidofovir can be used preemptively to prevent the development of disseminated adenovirus disease. Two of 16 patients developed disseminated adenovirus disease despite cidofovir therapy and one patient cleared adenovirus initially, but relapsed and died of disseminated adenovirus disease. The only data in the literature addressing the question of pre-emptive therapy are the recently published study by Bordigoni et al. 18 They treated eight patients: five with ribavirin and three with cidofovir. Two out of three patients treated with cidofovir cleared the infection compared to two of five patients treated with ribavirin. They also reported 11 patients with asymptomatic infections of whom 10 survived without therapy. However, they made the point that this untreated group was a low-risk group compared to the treated patients, since none of the patients had severe acute GVHD and most patients were grafted from HLA-identical sibling donors. In our study, the patient group treated for asymptomatic infections was a very special population. Most were children, 15 of 16 were grafted from unrelated or HLA-mismatched family donors, and 10 patients had received either CD-34 positively selected or T-depleted grafts. These patients have delayed immune reconstitution, and pre-emptive therapy of an asymptomatic infection may be especially indicated in this type of patient until sufficient restoration of T-cell function to clear the virus occurs.
The newly available diagnostic techniques such as antigen tests and PCR allow early diagnosis of adenovirus based on surveillance strategies. The sensitivity and specificity, and predictive values for adenovirus disease are currently unknown and therefore interpretation of our results is difficult. Techniques for determination of viral load are currently being developed and the application of such techniques to surveillance strategies will hopefully yield additional information, which can be used for design of studies aimed at assessing the effectiveness of preemptive therapy.
An additional complication regarding the evaluation of therapeutic strategies against adenovirus infections is the many different subtypes of adenoviruses. We know that different subtypes have different tissue propensities, but we do not currently know the relative risks of different subtypes for causing disseminated and invasive disease. The results of our study show no difference for the different subgroups in causing invasive disease or asymptomatic infections, although the numbers were small in all groups (data not shown).
The toxicity profile of cidofovir including nephrotoxicity and the potential for bone marrow toxicity has, until recently, limited its use in stem cell transplant patients. The results from this study support our previous results when cidofovir was given as therapy against CMV, namely that cidofovir can be given with an acceptable risk of toxicity. In our two studies, we have reported data on 126 stem cell transplant patients treated with cidofovir. The risk of renal toxicity in both studies combined was 26%. Most of the renal toxicity was mild (low-degree proteinuria or mild elevation of the serum creatinine), but some signs of renal impairment remained after discontinuation of cidofovir in approximately half of the patients who developed renal toxicity. However, bone marrow toxicity and other types of cidofovir toxicity (ophthalmologic and neurological) reported in AIDS patients treated for long periods with cidofovir were only rarely seen in our studies. Thus, the risk for nephrotoxicity because of cidofovir is significant in stem cell transplant recipients, and therefore the potential benefit of cidofovir therapy must be weighed against this risk.
We conclude that cidofovir has potential as an antiviral agent against adenovirus in allogeneic HSCT patients, in particular in adenovirus disease. The very high overall mortality underscores that the patient population in our study had a very high risk for severe post-transplant complications and presumably thereby had a very high risk for adenovirus infections. Therefore, additional, prospective, and controlled studies are necessary to formally evaluate cidofovir for therapy of adenovirus infections.
